Abstract
During this year there will be approximately 30 thousand deaths due to prostatic cancer in the United States (1). This mortality rate makes prostatic cancer the second commonest fatal tumor in males of all ages in America, and the leading cause of cancer death in men over the age of 55 (1). Besides a high annual mortality rate, prostatic cancer is now the most commonly diagnosed malignancy in males of all ages in the United States (1). These high annual incidence rates translate into the human reality that one of every 12 American white males will eventually develop clinical prostatic cancer during their lifetimes (2). Rates for American black males are even higher such that the lifetime risk for cancer is one out of every 10 (3). In addition, the annual incidence rate of clinical prostatic cancer has increased steadily since 1930 to the present time (4).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Silverberg, E., Lubera, J.A. Cancer Statistics, 1989. CA-Cancer Journal for Clinicians. 39:3–20, 1989.
Seidman, H., Mushinski, M.H., Gelb, S.K., Silverberg, E. Probabilities of eventually developing or dying of cancer: United States. CA-Cancer Journal for Clinicians, 35:36–56, 1985.
Mettlin, G. Epidemiology of prostate cancer in different population groups. Clinics in Oncology, 2:287–300, 1983.
Young, J.L., Percey, C.L. and Asire, A.J. Surveillance, epidemiology and end results: incidence and mortality data, 1973-1977. National Cancer Institute Monograph 57, DHHS Publication No. (NIH) 81–2330. 1981.
Scott, W.W., Menon, M., Walsh, P.C. Hormonal therapy of prostatic cancer. Cancer, 45:1929–1936, 1980.
Schulze, H., Isaacs, J.T., Coffey, D.S. A critical review of the concept of total androgen ablation in the treatment of prostatic cancer. IN Murphy, G.P., Khoury, S., Kuss, R., Chatelain, C., Denis, L. (eds.). Prostate cancer part a: research endocrine treatment, and histopathology progress in clinical and biological research. Vol. 243A pp 1–19. Alan R. Liss, Inc., New York, 1987.
Smith, J.A., Eyse, H.J., Roberts, T.S., Middleton, R.G. Transphenoidal hypophysectomy in the management of carcinoma of the prostate. Cancer, 53:2385–2387, 1984.
Menon, M., Walsh, P.C. Hormonal therapy for prostatic cancer. In Murphy, G.P. (ed). Prostatic Cancer, Littleton Mass, PSG Publ. Co., pp 175–200, 1979.
Devese, S.S., Silverman, D.T. Cancer incidence and morbidity trends in the United States: 1935-1974. J. Natl. Cancer Inst., 60:545–571, 1978.
Lepor, H., Ross, A., Walsh, P.C. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J. Urol., 128:335–340, 1982.
Raghavan, D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Seminars in Oncology, 15:371–389, 1988.
Prout, G.R., Leiman, B., Daly, J.J., MacLoughlin, R.A., Griffin, P.P., Young, H.H. Endocrine changes after diethylstilbestrol therapy. Urology, 7:148–155, 1976.
Sinha, A.A., Blackard, C.E., Seal, U.S. A critical analysis of tumor morphology and hormone treatment in the untreated and estrogen treated responsive and refractory human prostatic carcinoma. Cancer, 40:2836–2850, 1977.
Smolev, J.K., Heston, W.D.W., Scott, W.W., Coffey, D.S. An appropriate animal model for prostatic cancer. Cancer Treat Rep., 61:273–287, 1977.
Isaacs, J.T., Coffey, D.S. Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327 H adenocarcinoma. Cancer Res., 41:5070–5075, 1981.
Isaacs, J.T. Cellular factors in the development of resistance to hormonal therapy. In Bruchovsky, N., Goldie, J. (eds). Drug and Hormone Resistance in Neoplasia. Vol. 1, CRC Press, Boca Raton, Inc., pp 139–156, 1982.
Ellis, W. J., Isaacs, J.T. Effectiveness of complete vs partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic carcinomas. Cancer Res., 45:6041–6050, 1985.
Redding, T.W., Schally, A.V. Investigation of the combination of the agonist D-Trp-6-LHRH and the antiandrogen flutamide on the treatment of Dunning R-3327 H prostatic cancer model. The Prostate, 6:219–232, 1985.
Kung, T.T, Mingo, G.G, Siegel, M.I, Watnick, A.S. Effect of adrenalectomy, flutamide and leuprolide on the growth of the Dunning R-3327 prostatic carcinomas. The Prostate, 12:357–364, 1988.
Isaacs, J.T. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. The Prostate, 5:1–18, 1984.
Schulze, H., Isaacs, J., Senge, T. Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormone therapy. J. Urol., 137:909–914, 1987.
Isaacs, J.T. Relationship between tumor size and curability of prostate cancer by combined chemohormonal therapy. Cancer Res., 49:6290–6294, 1989.
Schackney, S.E., McCormack, G.W., Curhural, G.J. Growth rate patterns of solid tumours and their relation to responsiveness to therapy. Ann. Intern. Med., 89:107–113, 1978.
Tubiana, M., Malaise, E.P. Growth rate and cell kinetics in human tumours: some prognostic and therapeutic implications. In Symington, R., Carter, R.L. (eds.), Scientific Foundations of Oncology, Year Book Med Publishers, pp 126–136, 1975.
Helpap, B., Steins, R., Bruhl, P. Autoradiographic in vitro investigations of prostatic tissue with C-14 and H-3 thymidine double labelling method. Beitr Pathol Anta Allgem Path., 151:65–72, 1974.
Meyer, J.S., Sufrin, G., Martin, S.A.S. Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. J. Urol., 128:1353–1356, 1982.
Isaacs, J.T. Antagonistic effect of androgen on prostatic cell death. The Prostate, 5:545–558, 1984.
Wyllie, A.H., Kerr, J.F.R., Currie, A.R. Cell death: the significance of apoptosis. Int Rev Cytol., 68:251–306, 1986.
Kerr, J.F.R., Wyllie, A.H., Currie, A.R. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Brit J Cancer., 26:239–257, 1972.
Bowen, I.D., Lockshin, R.A. Cell death in biology and pathology. London: Chapman and Hill. 1981.
Wyllie, A.H. Glucocorticoid induces in thymocytes a nuclease-like activity associated with the chromatin condensation of apoptosis. Nature, 284:555–556, 1980.
Wyllie, A.H., Kerr, J.F.R., Macaskill, I.A.M., Currie, A.R. Adrenocortical cell deletion: the role of ACTH. J. Pathol., 111:85–94, 1973.
Umansky, S.R., Korol B.A., Nelipovich, P. A. In vivo DNA degradation in thymocytes of-irradiated or hydrocortisone-treated rats. Biochim Biophys Acta., 655:9–17, 1981.
Cohen, J.J., Duke, R.C. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J. Immunol., 132:38–42, 1984.
Wyllie, A.H., Morris, R.G., Smith, A.L., Dunlop, D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J. Pathol., 142:67–77, 1984.
Compton, M.M., Cidlowski, J.A. Rapid in vivo effects of glucocorticoids on the integrity of rat lymphocyte genomic deoxyribonucleic acid. Endocrinology, 118:38–45, 1986.
Kyprianou, N., Isaacs, J.T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology, 122:552–562, 1988.
Kyprianou, N., English, H.F., Isaacs, J.T. Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. The Prostate, 13:103–118, 1988.
English, H.F., Kyprianou, N., Isaacs, J.T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. The Prostate, 15:233–250, 1989.
Kerr, J.F.R., Searle, J. Deletion of cells byapoptosis during castration-induced involution of the rat prostate. Virchows Archiv B., 13:87–102, 1973.
Lesser, B., Bruchovsky, N. The effects of testosterone, 5-dihydrotestosterone and adenosine 3’,5’-monophosphate on cell proliferation and differentiation in rat prostate. Biochim Biophys Acta., 308:426–437, 1973.
Lee, C. Physiology of castration-induced regression of the rat prostate. Prog Clin Biol Res., 75A:145–159, 1982.
Sanford, M.L., Searle, J.W., Kerr, J.F.R. Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation. Pathology, 16:406–410, 1984.
Stanisic, T., Sadlowski, R., Lee, C., Grayhack, J.T. Partial inhibition of castration-induced ventral prostate regression with actinomycin D and cycloheximide. Invest Urol., 16:19–22, 1978.
Lee, C., Sensibar, J. A. Protein of the rat prostate: Synthesis of new proteins in the ventral lobe during castration-induced regression. J. Urol., 138:903–908, 1985.
Saltzman, A.G., Hiipakka, R.A., Chang, C., Liao, S. Androgen repression of the production of a 29 kilodalton protein and its mRNA in the rat ventral prostate. J. Biol. Chem., 262:432–437, 1987.
Montpetit, M.L., Lawless, K.R., Tenniswood, M. Androgen repressed messages in the rat ventral prostate. The Prostate, 8:25–36,1986.
Buttyan, R., Zaker, Z., Lockshin, R., Wolgemuth, D. Cascade induction of c-fos, c-myc and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol Endocrinol., 2:650–657, 1988.
Kyprianou, N., Isaacs, J.T. Expression of transforming growth factor-in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol, 3:1515–1522, 1989.
Connor, J., Sawdzuk, I.S., Benson, M.C., Tomashersky, P., O’Tool K.M., Olsson, C.A., Buttyan, R. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. The Prostate, 13:119–130, 1988.
Nicotera, P., McConkey, D.J., Jones, D.P., Orrenius, S. ATP stimulates Ca2+ uptake and increasesthe free Ca2+ concentration in isolated rat liver nuclei. Proc Natl Acad Sci USA, 86:453–457, 1989.
Jones, D.P., McConkey, D.J., Nicotera, P., Orrenius, S. Calcium-activated DNA fragmentation in rat liver nuclei. J. Biol Chem., 264:6398–6403, 1989.
Viskochil D.H., Perry, S.T., Lea, D.A., Stafford, D.W., Wilson, E.M., French, F.S. Isolation of two genomic sequences encoding the mr-1400 subunit of rat prostatein. J. Biol Chem., 258:8861–8866, 1983.
Seto, S., Carrera, C.J., Kubota, M., Wasson, D.B., Carson, D.A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin Invest., 75:377–383, 1985.
Carson, D.A., Seto, S., Wasson, D.B., Carrera, C.J. DNA strand breaks, NAD metabolism, and programmed cell death. Exp Cell Res., 164:273–281, 1986.
Berger, N.A. Poly(ADP-ribose) in the cellular response to DNA damage. Radiation Res., 101:4–15, 1985.
Berger, N.A., Berger, S.J., Sudar, D.C., Distelhorst, C.W. Role of nicotinamide adenine dinucleotide and adenosine triphosphate in glucocorticoid-induced cytotoxicity in susceptible lymphoid cells. J. Clin Invest., 79:1558–1563, 1987.
McKeehan, W.L., Adams, P.S. Heparin-binding growth factor/prostatropin attenuates inhibition of rat prostate tumor epithelial cell growth by transforming growth factor type. In Vitro Cell Dev Biol., 24:243–246, 1988.
Kyprianou, N., Isaacs, J.T. Identification of a cellular receptor for transforming growth factor in rat ventral prostate and its negative regulation by androgens. Endocrinology, 123:2124–2131, 1988.
van Steenbrugge, G.J., Groen, M., Romijn, J.C., Schroder, F. Biological effects of hormonal treatment regimens on a transplantable human prostate tumor line (PC-82). J. Urol., 131:812–817, 1984.
Kyprianou, N., Isaacs, J.T. Thymine-less death in androgen-independent prostatic cancer cells. Biochem Biophys Res Comm., 165:73–81, 1989.
Tucker, R.W., Meade-Cobun, K., Loats, H. Measurement of free intracellular calcium (Cai) in fibroblasts. Digital image analysis of Fur a 2 fluorescence. In Fiskum, G. (ed), Plenum Publ Corp, pp 239–248, 1989.
Bettuzzi, S., Hiipakka, R.A., Gilna, P., Liao, S. Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem J., 257:293–296, 1989.
Sylvester, S.R., Skinner, M.K., Griswold, M.D. A sulfated glycoprotein synthesized by Sertoli cells and by epididymal cells is a component of the sperm membrane. Biol Reprod., 31:1087–1101, 1984.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kyprianou, N., Martikainen, P., Isaacs, J.T. (1991). Therapeutic Approaches to Activating Programmed Cell Death of Androgen-Independent Prostatic Cancer Cells. In: Karr, J.P., Coffey, D.S., Smith, R.G., Tindall, D.J. (eds) Molecular and Cellular Biology of Prostate Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3704-5_4
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3704-5_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6647-8
Online ISBN: 978-1-4615-3704-5
eBook Packages: Springer Book Archive